COMMUNIQUÉS West-GlobeNewswire
-
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
19/02/2026 -
Aaptiv Launches New MSK App in Partnership With movr
19/02/2026 -
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
19/02/2026 -
Human Appeal reaches over 862,000 people with food, water and life-saving emergency response amid ongoing Sudan conflict
19/02/2026 -
Family Insight Appoints Kyle Williamson as Vice President of Business Development, Accelerates Expansion and Partnerships in Value-Based Care
19/02/2026 -
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
19/02/2026 -
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
19/02/2026 -
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
19/02/2026 -
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
19/02/2026 -
20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth
19/02/2026 -
Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan
19/02/2026 -
Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value
19/02/2026 -
Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk
19/02/2026 -
Burcon Chiropractic Launches Meniere’s Disease Treatment Clinical Trial in Grand Rapids
19/02/2026 -
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
19/02/2026 -
Dror Ortho-Design Receives 510(k) FDA Clearance for Next-Generation Smile Correction Solution
19/02/2026 -
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
19/02/2026 -
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
19/02/2026 -
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
19/02/2026
Pages